CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of CAMP4 Therapeutics Corporation (NASDAQ:CAMP) have been given an average rating of “Moderate Buy” by the nine brokerages that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $8.3571.

Several brokerages have recently weighed in on CAMP. JPMorgan Chase & Co. upgraded CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and raised their price target for the company from $5.00 to $9.00 in a report on Tuesday, June 16th. Chardan Capital set a $6.50 price objective on shares of CAMP4 Therapeutics and gave the company a “buy” rating in a research report on Wednesday, June 10th. Rodman & Renshaw started coverage on shares of CAMP4 Therapeutics in a research note on Tuesday, April 14th. They set a “buy” rating and a $7.00 price objective for the company. Zacks Research cut shares of CAMP4 Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 15th. Finally, Weiss Ratings downgraded shares of CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 21st.

CAMP4 Therapeutics Stock Down 0.5%

CAMP stock opened at $4.22 on Tuesday. CAMP4 Therapeutics has a twelve month low of $1.32 and a twelve month high of $7.75. The firm has a market cap of $219.14 million, a PE ratio of -1.79 and a beta of 0.22. The business has a 50 day moving average of $4.02 and a 200 day moving average of $4.29.

Insiders Place Their Bets

In other CAMP4 Therapeutics news, Director Richard A. Young acquired 16,378 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were acquired at an average cost of $1.65 per share, with a total value of $27,023.70. Following the transaction, the director owned 186,388 shares of the company’s stock, valued at $307,540.20. The trade was a 9.63% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In the last ninety days, insiders have purchased 36,031 shares of company stock valued at $59,451. 21.69% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. SummitTX Capital L.P. purchased a new position in CAMP4 Therapeutics in the 1st quarter worth about $1,497,000. EcoR1 Capital LLC purchased a new stake in shares of CAMP4 Therapeutics during the 4th quarter valued at about $1,992,000. Jefferies Financial Group Inc. purchased a new stake in shares of CAMP4 Therapeutics during the 4th quarter valued at about $70,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of CAMP4 Therapeutics in the fourth quarter worth approximately $61,000. Finally, Jane Street Group LLC bought a new stake in shares of CAMP4 Therapeutics in the fourth quarter worth approximately $157,000.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.